References
- Fritsche TR, Kirby JT, Jones RN. In vitro activity of tige-cycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect 2004; 49: 201–209.
- Bradford P A, Weaver-Sands DT, Petersen PJ. In vitro ac-tivity of tigecycline against isolates from patients enrolled in phase
- clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (Suppl. 5), 5315—S332.
- Hoban DS, Bouchillon BJ, Johnson J, Dowzicky M. In vitro activity of tigecycline against 6792 gram-negative and gram-pos-itive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn Microbiol Infect Dis 2005; 52: 215–227.
- Jones CH, Petersen PJ. Tigecycline: a review of preclinical and clinical studies of the first-in class glycylcycline antibiotic. Drugs Today 2005; 637–659.
- Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antimicrobial activities of a novel glycylcy-cline, the 9-tbutylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738–744.
- CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards: M/-A7. Wayne, PA: Clinical and laboratory Standards Institute, 2006.
- Bradford PA, Petersen PJ, Young M et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standard-ize the test method. Antimicrob Agents Chemother 2005; 49: 3903–3909.
- NCCLS. Methods for determining bactericidal activity of antimicrobial agents: Approved guidelines M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 19, 1999.
- Craig WA, Gudmundsson S. Postantibiotic effect. In Lorian V. ed. Antibiotics in Laboratory Medicine. Baltimore: Williams & Wilkins, 1996: 296-305.
- Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test systems (AST)-guidance for industry. U.S. Food and Drug Administration, Washington, DC, [Online] 2003. http://www.fda.gov/cdrh/ oivd/guidance/631. pdf. .
- Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneu-mococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and - resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085–1088.
- van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo phar-macodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943–949.
- Mercier RC, Kennedy C, Meadows C. Antimicrobial ac-tivity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22, 1517–1523.